ELVN
Enliven Therapeutics, Inc.
$41.54
-0.71
(-1.68%)
Mkt Cap
2.53B
Volume
616,354
52W Range
14.785-48.53
Sector
Healthcare
Beta
0.45
EPS (TTM)
-1.64
P/E Ratio
-8.42
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (103.69M) | (89.02M) | (71.58M) | (37.66M) | (24.74M) | (18.97M) | (23.46M) | (11.34M) | 0 |
| EPS | -1.83 | -1.89 | -2.01 | -6.03 | -3.17 | -4.31 | -5.43 | -2.62 | 0.00 |
| Free Cash Flow | (70.46M) | (73.24M) | (61.42M) | (32.69M) | (19.32M) | (8.99M) | (22.02M) | (8.78M) | (8.79M) |
| FCF / Share | -1.24 | -1.56 | -1.73 | -5.23 | -2.47 | -2.05 | -5.10 | -2.03 | -2.03 |
| Operating CF | (70.30M) | (73.19M) | (61.27M) | (32.08M) | (19.13M) | (8.53M) | (21.88M) | (8.78M) | (8.79M) |
| Total Assets | 476.17M | 325.76M | 271.87M | 83.30M | 113.33M | 90.84M | 33.30M | 7.71M | 10.22M |
| Total Debt | 399,000 | 0 | 335,000 | 323,000 | 159,000 | 0 | 0 | 0 | 660,000 |
| Cash & Equiv | 98.90M | 124.12M | 100.14M | 75.54M | 110.02M | 47.70M | 4.94M | 7.38M | 9.67M |
| Book Value | 459.60M | 309.85M | 245.91M | (76.83M) | 106.86M | 84.44M | (48.85M) | (26.32M) | (15.53M) |
| Return on Equity | -0.23 | -0.29 | -0.29 | N/A | -0.23 | -0.22 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.63M) | (29.67M) | (20.15M) | (25.34M) | (28.54M) | (23.18M) | (23.16M) | (19.95M) | (22.74M) | (19.37M) | (20.77M) | (16.72M) |
| EPS | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.47 | -0.51 | -0.41 |
| Free Cash Flow | (19.29M) | (15.84M) | (13.28M) | (17.20M) | (24.15M) | (17.20M) | (12.21M) | (20.44M) | (23.38M) | (12.50M) | (15.91M) | (12.14M) |
| FCF / Share | -0.31 | -0.28 | -0.21 | -0.33 | -0.48 | -0.35 | -0.25 | -0.43 | -0.56 | -0.30 | -0.39 | -0.30 |
| Operating CF | (19.29M) | (15.84M) | (13.28M) | (17.06M) | (24.13M) | (17.20M) | (12.19M) | (20.43M) | (23.36M) | (12.48M) | (15.89M) | (12.05M) |
| Total Assets | 464.85M | 476.17M | 490.88M | 503.89M | 302.57M | 325.76M | 305.43M | 327.04M | 342.78M | 271.87M | 274.04M | 288.50M |
| Total Debt | 302,000 | 399,000 | 387,000 | 580,000 | 365,000 | 0 | 85,000 | 169,000 | 252,000 | 335,000 | 332,000 | 329,000 |
| Cash & Equiv | 132.18M | 98.90M | 101.73M | 119.44M | 101.70M | 124.12M | 100.62M | 96.87M | 149.16M | 100.14M | 73.85M | 125.72M |
| Book Value | 453.37M | 459.60M | 476.12M | 488.47M | 288.30M | 309.85M | 288.40M | 304.93M | 317.71M | 245.91M | 261.75M | 278.99M |
| Return on Equity | -0.05 | -0.06 | -0.04 | -0.05 | -0.10 | -0.07 | -0.08 | -0.07 | -0.07 | -0.08 | -0.08 | -0.06 |
ELVN News
Enliven Therapeutics to Present at Upcoming Investor Conferences
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference